San Mateo, CA (PRWEB) June 13, 2012
Entelos - a premier provider of in silico modeling and simulation products and consulting services that help pharmaceutical and consumer product companies make better decisions in their product development process, modeled the mechanistic effects of glycogen phosphorylase inhibition in its metabolism PhysioLab platform. This enzyme target is of significant interest to drug companies developing treatments for Type 2 diabetes, and has shown promise in studies using diabetic rats. Efficacy in rats does not always translate to human due to differences in the physiology of the two species. This effect and its underlying mechanism were exposed in this project that being featured as a poster at the American Diabetes Association (ADA) 72nd annual Scientific Session June 8-12, in Philadelphia.
“Translation from animal data to human is often a source of disappointing outcomes after much investment of time and cost. Our ability to explain these phenomena through mechanism-based predictions is revolutionizing this fundamental research challenge ,” said Shawn O’Connor, president and CEO of Entelos.
Inhibitors of glycogen phosphorylase (GP), a key enzyme that regulates the mobilization of glucose from glycogen, have demonstrated sustained glucose lowering in rodent models of type 2 diabetes (T2D). The therapeutic potential of GP inhibition for the treatment of T2D in humans was evaluated using Entelos’ Metabolism PhysioLab platform, a large-scale mathematical model of whole-body metabolism. The ADA poster: Inter-species differences contributing to poor translatability of sustained glucose lowering effects of glycogen phosphorylase inhibition from rodent to human predicted in a mechanistic model of metabolic disease can be viewed at http://www.entelos.com/resources/.
Entelos has fully developed platforms in multiple disease areas in addition to Metabolism (with diabetes and obesity) including: Cardiovascular Disease, Rheumatoid Arthritis, Hypertension (with heart and kidney failure), Dermatology, Hematology, Infection, Nutrition and Veterinary Nutrition.
Entelos is an in silico modeling and simulation software and services company delivering predictive technologies reducing risk, time, and cost of product development for pharmaceutical, biotechnology, nutrition and consumer products customers. The Company’s PhysioLab systems biology platforms generate virtual patient populations providing highly predictive analyses to develop safer and more effective drugs, foods and consumer products. Entelos’ understanding of patient variability has significant application to the emerging field of personalized medicine. The Company is headquartered in San Mateo, California. For more information, please visit http://www.entelos.com.
Wendy Shelton, 650-572-5430
VP, Corporate Communications